Intelligent Bio Solutions Reports 98.2% Accuracy in Codeine Study, Accelerates FDA 510(k) Submission to September
INBS sits 73% above its 52-week low of $1.52 on elevated volume (31× avg).
Summary
Intelligent Bio Solutions announced strong codeine detection study results—98.2% accuracy and 94.6% sensitivity—and accelerated its FDA 510(k) submission to September 2026.
Key Events · Product Development and Regulatory · INBS
-
Codeine Study Hits 98.2% Accuracy
A multi-site Method Comparison Study across three U.S. clinical sites showed 98.2% accuracy, 94.6% sensitivity, and 100% specificity for opiate codeine detection.
-
Sensitivity Jumps from 82% to 94.6%
The new results represent a substantial improvement over the prior study announced November 2024, which reported approximately 94% accuracy and 82% sensitivity.
-
FDA 510(k) Submission Accelerated to September 2026
With all data collection complete, the company now expects to submit its 510(k) application in September 2026, ahead of the previously stated H2 2026 timeline.
-
U.S. Market Entry Depends on FDA Clearance
FDA clearance is the critical gate for the company's planned entry into the U.S. workplace drug screening market, a key growth opportunity given the going-concern warning in the recent 10-K.
Analysis · INBS · Industrial Applications And Services
The latest Method Comparison Study marks a major leap in sensitivity—from roughly 82% in the prior study to above 94%—lifting overall accuracy above 98% with 100% specificity. This closes the key performance gap that had been holding back the FDA 510(k) submission. Management now expects to file the application in September 2026, a concrete acceleration from the previously stated H2 2026 window. For a company with a going-concern warning and a $7.4M market cap, FDA clearance is the single most important near-term catalyst for U.S. market entry and revenue expansion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $2.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.